FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Inc., a Toronto-based biopharmaceutical company, has officially submitted its Clinical Trial Application (CTA) for a Phase-1b trial aimed at evaluating the safety and efficacy of unbuzzd™, a proprietary beverage. Targeting healthy volunteers under induced alcohol intoxication, the trial, known as the METAL-1 TRIAL, awaits review by an ethics committee in Australia. The company anticipates the commencement of volunteer recruitment in April, following approval.

Unbuzzd™, a dietary supplement intended for marketing in the United States, combines natural ingredients, vitamins, and food supplements designed to enhance cognition and assist in alcohol metabolism. Dr. Andrzej Chruscinski of FSD Pharma emphasized the product's development through extensive efforts and the aim to assess its impact on alcohol consumers.

John Duffy of Celly Nutrition highlighted unbuzzd™'s functionality in accelerating alcohol metabolism and improving post-consumption cognition. Former Coca-Cola Vice President and retired CEO of Celsius Energy, Gerry David, expressed optimism about unbuzzd™'s potential mainstream success and its benefits for consumers.

This clinical trial represents FSD Pharma's continued commitment to delivering innovative solutions for alcohol misuse disorders among other health challenges. The company's broad portfolio includes ongoing R&D projects and strategic investments aimed at combating neurodegenerative and metabolic disorders.